Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial

NCT03601507 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT03601507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03601507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Terminated
Start date
March 11, 2019
Completion date
May 24, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cdkn2a-p16 positive, hpv positive oropharyngeal squamous cell carcinoma, stage i oropharyngeal squamous cell carcinoma ajcc v7, stage ii oropharyngeal squamous cell carcinoma ajcc v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7